Background Patients with relapsed or refractory acute myeloid leukemia (AML) with
mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to …

Patients with refractory or relapsed acute myeloid leukemia (R/R AML) have a poor
prognosis, with a high unmet medical need. Idasanutlin is a small-molecule inhibitor of …

Acute myeloid leukaemia (AML) incidence is age dependent, rising markedly in patients
aged! 60 years. Ageing of the European population may therefore contribute to the reported …

Recent advances in the description of the tumor microenvironment of acute myeloid
leukemia, including the comprehensive analysis of the leukemic stem cell niche and clonal …

Chemoresistance and relapse are the leading cause of AML-related deaths. Utilizing single-
cell RNA sequencing (scRNA-seq), we dissected the cellular states of bone marrow samples …

The phase 3 MIRROS (MDM2 antagonist Idasanutlin in Relapsed or Refractory acute
myeloid leukemia [AML] for Overall Survival) trial (NCT02545283) evaluated the efficacy and …

The prognosis remains poor for patients with relapsed or refractory (r/r) acute myeloid
leukemia; thus, novel therapies are needed. We evaluated idasanutlin—a new, potent …

Considerable progress has been made in the treatment of acute myeloid leukemia (AML).
However, current therapeutic results are still unsatisfactory in untreated high-risk patients …

The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is
discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 …

Simple Summary Acute myeloid leukemia is the most common type of acute leukemia in
adults. It is associated with poor outcomes, especially in older patients. Treatments based …